Satisfaction | Model | Interacted factors | p-value for interaction |
---|---|---|---|
Cost of treatment | Subjective model | Disease duration and EQ5D | < 0.001 |
Pain VAS and EQ5D | 0.004 | ||
Objective model | Age and b/tsDMARDs use | 0.011 | |
Sex and log-transformed CRP | < 0.001 | ||
Disease duration and history of musculoskeletal surgery | 0.011 | ||
Log-transformed CRP and physician VAS | 0.012 | ||
History of musculoskeletal surgery and methotrexate use | 0.026 | ||
History of musculoskeletal surgery and b/tsDMARDs use | < 0.001 | ||
Effect of treatment | Subjective model | Disease duration and EQ5D | 0.007 |
General VAS and EQ5D | 0.013 | ||
Objective model | TJC and history of musculoskeletal surgery | 0.020 | |
Age and methotrexate use | 0.031 | ||
SJC and methotrexate use | 0.002 | ||
Physician VAS and methotrexate use | < 0.001 | ||
ADL | Subjective model | Disease duration and sex | 0.017 |
Pain VAS and EQ5D | 0.024 | ||
General VAS and EQ5D | 0.030 | ||
Objective model | History of musculoskeletal surgery and Steinbrocker stage | 0.004 | |
Methotrexate use and b/tsDMARDs use | 0.022 | ||
Global treatment | Subjective model | General VAS and EQ5D | < 0.001 |
Objective model | Age and Steinbrocker stage | 0.022 | |
Age and b/tsDMARDs use | 0.005 | ||
TJC and physician VAS | 0.004 |